Liposome Formulation Specific Testing for Drug Product Release

Methods Regulatory Advantages Contact Us FAQ

Liposome formulation-specific testing is a dedicated service for liposomal injectable drug product release. It systematically quantifies encapsulation efficiency, particle size distribution, and zeta potential, with methods designed to align with USP, FDA, and pharmacopoeia requirements for nanomedicines.

Liposomes are nano‑scale vesicles composed of one or more phospholipid bilayers. They are among the most widely used nanocarriers for drug delivery, encapsulating hydrophilic drugs (in the aqueous core) and hydrophobic drugs (in the bilayer) to improve stability, bioavailability, and targeting.

Creative Biogene provides one‑stop services from liposome release testing to IND/BLA submission data packages, aligned with FDA Liposome Drug Products Guidance (2018) and USP <729>. Data are ready for CMC sections.

Technical Principles

Encapsulation Efficiency (EE)

EE is the percentage of the total drug that is encapsulated within liposomes. It directly determines product efficacy and safety – a free drug may cause toxicity, altered pharmacokinetics, and reduced efficacy.

Method	Principle	Separation Efficiency	Throughput	Best For
Microcolumn centrifugation	Size‑exclusion centrifugation	>90%	Low–medium	Most liposome types
nPEC (nanoparticle exclusion chromatography)	Size‑exclusion chromatography	>90%	High	All types, automated, no pretreatment
Ultracentrifugation	Density difference (100k–200k × g)	85–95%	Low	Larger liposomes (>100 nm)
Dialysis	Membrane diffusion (MWCO 10–50 kDa)	80–90%	Low	Stable liposomes, slow

nPEC is a recent advancement (2025) with >90% separation efficiency for both lipophilic and hydrophilic drugs, suitable for high‑throughput release testing.

Particle Size Distribution – Dynamic Light Scattering (DLS)

DLS is the gold standard for liposome size measurement. It analyzes the Brownian motion of suspended nanoparticles to calculate the hydrodynamic diameter via the Stokes‑Einstein equation. USP <729> recognizes DLS for 1‑1000 nm particles, providing Z‑average (mean size) and polydispersity index (PDI). DLS is semi‑quantitative and complements light obscuration.

Zeta Potential – Electrophoretic Light Scattering (ELS)

Zeta potential measures liposome surface charge density, a key indicator of colloidal stability. High absolute zeta potential (positive or negative) generates electrostatic repulsion, preventing aggregation. ELS measures electrophoretic mobility under an electric field and calculates zeta potential via the Henry equation.

Regulatory Basis

Document	Key Requirement
FDA Liposome Drug Products Guidance (2018)	Physicochemical characterization must include particle size, size distribution, morphology, and surface charge (zeta potential). Liposomes are complex and sensitive to CMC changes.
USP <729>	Globule size distribution in lipid injectable emulsions. DLS for 1‑1000 nm (semi‑quantitative); light obscuration for 1.3‑400 μm (counting).
USP <786>	General methods for particle size distribution.
ICH Q6B	Specification framework for biologics; applicable to liposome drug products.
ICH Q5C	Stability testing – monitoring of critical quality attributes.

Creative Biogene's Advantages

Full coverage of three critical quality attributes: EE, particle size, and zeta potential.
FDA Liposome Guidance alignment – supports IND/BLA submissions.
Multiple EE methods – microcolumn centrifugation, nPEC, ultracentrifugation, dialysis; flexible selection based on liposome type and drug properties.
nPEC advanced platform – automated, no sample pretreatment, >90% separation efficiency, ideal for high‑throughput release.
Gold standard DLS – high‑sensitivity system providing Z‑average, PDI, and distribution curves (intensity/volume/number).
High‑precision ELS – accurate zeta potential measurement for colloidal stability assessment.
GLP/GMP data package – reports designed for regulatory submissions.

Contact Us

For a customized testing strategy, method validation, or IND/BLA submission support for your liposome formulation, contact Creative Biogene’s technical team.

FAQ

Q1: Are EE, particle size, and zeta potential all mandatory for liposome release?

Yes. FDA Liposome Drug Products Guidance (2018) requires physicochemical characterization covering size, distribution, morphology, and surface charge. EE is a core quality attribute directly affecting efficacy and safety. All three are mandatory.

Q2: How to choose between microcolumn centrifugation and nPEC for EE?

Microcolumn centrifugation is widely used and suitable for most liposome types, but requires manual column preparation. nPEC is a 2025 recommended advanced method – automated, no pretreatment, >90% separation efficiency, suitable for all nanoparticle types and high‑throughput release. Creative Biogene recommends the optimal method based on liposome type and throughput needs.

Q3: How do particle size and EE change during stability studies?

During storage: size may increase due to aggregation or fusion (correlates with zeta potential drop); PDI may widen (broader distribution); EE may decrease due to drug leakage (membrane stability); zeta potential may drop (reduced stability). ICH Q5C requires monitoring these attributes. Creative Biogene assists with stability study design and trend analysis.

* For research use only. Not intended for any clinical use.

Quick Inquiry